Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective.

Gerbasi, Margaret E; Stellato, Daniel; Ghate, Sameer R; Ndife, Briana; Moynahan, Aaron; Mishra, Dinesh; Gunda, Praveen; Koruth, Roy; Delea, Thomas E.
J Med Econ; 22(12): 1243-1252, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31223037